AXGN: Q3 growth lifted FY revenue guidance to at least $290M

What happened

Third-quarter revenue grew 26.2% from a year earlier to $75.8M, with adjusted net income of $13.1M and adjusted EBITDA of $13.4M. Full-year revenue guidance rose to at least $290M, including a contribution from BioCircuit.

Confirmed

Global impact / market context

Faster sales can help Axogen cover fixed costs and turn more of each sale into profit, which matters for a company still working toward sustained earnings. The higher full-year revenue target signals management expects demand to hold up.

Analyst inference

Rising revenue guidance can shift investor expectations for future sales and earnings, potentially supporting the stock if results keep pace. The BioCircuit contribution means part of the outlook depends on that added business rather than existing products alone.

Analyst inference

What to watch

1. Axogen's fourth-quarter revenue and whether it keeps the pace needed to reach at least $290M for the full year. Confirmed
2. How much of the full-year revenue guidance depends on BioCircuit, since that mix affects whether growth comes from new or existing products. Analyst inference
3. Whether higher revenue carries through to adjusted net income and adjusted EBITDA, which show profit after certain accounting adjustments. Analyst inference

Evidence

• Original source link unavailable